🔴 Immunitybio is trading 4.8% down today with no clear company-specific catalyst

Immunitybio is trading at $8.22, down -4.80%, with no clear company-specific catalyst identified.

• The recent ANKTIVA approval expansion and bladder-cancer trial update are prior news, not evidence of a new October 22 catalyst.
• Broader risk-off sentiment is a plausible factor as markets retreated with rising oil amid Strait of Hormuz tensions and technology-spending concerns. Major indexes were lower, but this does not establish the precise cause of Immunitybio’s decline.